D.E. Shaw & Co
NTLA icon

D.E. Shaw & Co’s Intellia Therapeutics NTLA Stock Holding History

D.E. Shaw & Co’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-35,100
Closed -$250K – 4601
2025
Q1 		$250K Sell
35,100
-29,400
-46% -$297K ﹤0.01% 3841
2024
Q4 		$752K Buy
64,500
+17,600
+38% +$275K ﹤0.01% 3377
2024
Q3 		$964K Buy
46,900
+16,900
+56% +$390K ﹤0.01% 3302
2024
Q2 		$671K Buy
+30,000
New +$714K ﹤0.01% 3440
2021
Q4 		– Sell
-15,000
Closed -$2.01M – 5606
2021
Q3 		$2.01M Hold
15,000
– – ﹤0.01% 3031
2021
Q2 		$2.43M Buy
+15,000
New +$1.17M ﹤0.01% 2749

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return